Clovis Oncology Stock Cash Per Share
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology fundamentals help investors to digest information that contributes to Clovis Oncology's financial success or failures. It also enables traders to predict the movement of Clovis Stock. The fundamental analysis module provides a way to measure Clovis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clovis Oncology stock.
Clovis |
Clovis Oncology Company Cash Per Share Analysis
Clovis Oncology's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Clovis Oncology Cash Per Share | 0.65 X |
Most of Clovis Oncology's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Clovis Oncology has a Cash Per Share of 0.65 times. This is 85.06% lower than that of the Biotechnology sector and 84.99% lower than that of the Health Care industry. The cash per share for all United States stocks is 87.03% higher than that of the company.
Clovis Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clovis Oncology's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clovis Oncology could also be used in its relative valuation, which is a method of valuing Clovis Oncology by comparing valuation metrics of similar companies.Clovis Oncology is currently under evaluation in cash per share category among related companies.
Clovis Fundamentals
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 148.76 M | |||
| Gross Profit | 115.3 M | |||
| EBITDA | (224.76 M) | |||
| Net Income | (264.52 M) | |||
| Cash And Equivalents | 94.58 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 436.77 M | |||
| Debt To Equity | 810.00 % | |||
| Current Ratio | 1.17 X | |||
| Book Value Per Share | (2.89) X | |||
| Cash Flow From Operations | (196.06 M) | |||
| Short Ratio | 4.63 X | |||
| Earnings Per Share | (2.08) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 413 | |||
| Beta | 0.22 | |||
| Market Capitalization | 11.77 M | |||
| Total Asset | 472.83 M | |||
| Retained Earnings | (2.3 B) | |||
| Working Capital | 464.12 M | |||
| Current Asset | 539.7 M | |||
| Current Liabilities | 75.58 M | |||
| Z Score | -5.6 | |||
| Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Clovis Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clovis Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clovis Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Clovis Stock
| 0.86 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.74 | DD | Dupont De Nemours Buyout Trend | PairCorr |
| 0.71 | AXP | American Express Earnings Call This Week | PairCorr |
| 0.7 | JPM | JPMorgan Chase Financial Report 12th of July 2024 | PairCorr |
| 0.66 | BRK-A | Berkshire Hathaway Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Clovis Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clovis Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clovis Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clovis Oncology to buy it.
The correlation of Clovis Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clovis Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clovis Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clovis Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |